Oxford BioDynamics Plc (OXBOF)
OTCMKTS · Delayed Price · Currency is USD
0.0020
-0.0015 (-42.86%)
At close: Jan 23, 2026
Oxford BioDynamics Revenue
In the fiscal year ending September 30, 2025, Oxford BioDynamics had annual revenue of 1.10M GBP with 72.17% growth. Oxford BioDynamics had revenue of 508.00K in the half year ending September 30, 2025, with 75.17% growth.
Revenue
1.10M GBP
Revenue Growth
+72.17%
P/S Ratio
12.31
Revenue / Employee
26.71K GBP
Employees
41
Market Cap
18.12M USD
Revenue Chart
* This company reports financials in GBP.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2025 | 1.10M | 459.00K | 72.17% |
| Sep 30, 2024 | 636.00K | 126.00K | 24.71% |
| Sep 30, 2023 | 510.00K | 356.00K | 231.17% |
| Sep 30, 2022 | 154.00K | -187.00K | -54.84% |
| Sep 30, 2021 | 341.00K | -115.00K | -25.22% |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Global Cord Blood | 196.10M |
| Centogene | 53.65M |
| Bioqual | 46.54M |
| Interpace Biosciences | 41.92M |
| Psychemedics | 19.69M |
| China New Energy Group Company | 12.51M |
| Aspira Women's Health | 9.34M |
| Longduoduo Company | 2.72M |
Oxford BioDynamics News
- 1 year ago - Oxford Biodynamics to present on its line of EpiSwitch® products for companion diagnostics in cancer immunotherapy at the 14th World Summit for Clinical Biomarkers and Companion Diagnostics in Boston, MA. - Business Wire
- 1 year ago - Oxford BioDynamics part of consortium shortlisted for Strategic Government Initiative to Improve Cancer Immunotherapy - Business Wire